treatment of overactive bladder

Comparing effect of cutaneous posterior tibial nerve stimulation with medical treatment with Solifenacin in patients with overactive bladder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151123025202N4

Enrollment

Registered

2019-11-28

Start date

2019-11-21

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Over Active Bladder. Overactive bladder

Interventions

Intervention 1: Intervention group:. Intervention 2: Control group: Receiving Solifenacin is given 5 mg twice daily for 12 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Clinical Diagnosis of overactive bladder minimum age of 18 years old negative result of Urine culture

Exclusion criteria

Exclusion criteria: pregnant women People with Pacemaker Inflammatory or neurological origin History of spinal cord trauma Central nervous system lesions Metabolic disease or genetic syndromes history of abdominal surgery History of pelvic fractures Eurogenital Anomalies history of taking anticholinergic drugs for six months Psychological Disorders

Design outcomes

Primary

Measure	Time frame
Improved quality of life due to urinary incontinence three months after treatment The outcome of this study is evaluated by a standard questionnaire. Timepoint: 1 and 3 months after treatment. Method of measurement: The q-OAB questionnaire will be used to collect the frequency of urinary frequency, urgency, and urgency incontinence for 3 days. q-OAB is a quality of life questionnaire designed to assess symptoms of health-related symptoms and quality of life (HRQL) in patients with or without incontinence and OAB. q-OAB contains 4 subset include social, interaction, concern, coping and HRQL.	—

Measure

Time frame

Improved quality of life due to urinary incontinence three months after treatment The outcome of this study is evaluated by a standard questionnaire. Timepoint: 1 and 3 months after treatment. Method of measurement: The q-OAB questionnaire will be used to collect the frequency of urinary frequency, urgency, and urgency incontinence for 3 days. q-OAB is a quality of life questionnaire designed to assess symptoms of health-related symptoms and quality of life (HRQL) in patients with or without incontinence and OAB. q-OAB contains 4 subset include social, interaction, concern, coping and HRQL.

—

Secondary

Measure	Time frame
Improving patients' quality of life is a secondary outcome of this study. Timepoint: 1 and 3 months after treatment onset. Method of measurement: Outcoms are measured using the summary form of the Bladder Hyperactivity Questionnaire, which contains 25 questions. The questionnaire consists of two parts: 6 questions (symptoms of bladder hyperactivity) and 19 questions (quality of life associated with bladder hyperactivity).	—

Measure

Time frame

Improving patients' quality of life is a secondary outcome of this study. Timepoint: 1 and 3 months after treatment onset. Method of measurement: Outcoms are measured using the summary form of the Bladder Hyperactivity Questionnaire, which contains 25 questions. The questionnaire consists of two parts: 6 questions (symptoms of bladder hyperactivity) and 19 questions (quality of life associated with bladder hyperactivity).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Moradi

Hamedan University of Medical Sciences

a.moradi@umsha.ac.ir+98 81 3838 0097

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026